MRC Agrotech reported audited FY26 standalone revenue of ₹85.46 crore and net profit of ₹1.17 crore. The company acquired Marsapi Lifesciences and assigned receivables. Auditors noted GST compliance and business concentration risks.
MRC Agrotech FY26 Results Show Growth Amidst Audit Observations
Standalone FY26 Revenue: ₹85.46 crore (₹8,545.89 lakh) Standalone FY26 Net Profit: ₹1.17 crore (₹116.55 lakh) Reader Takeaway: Growth in revenue and profit, but watch concentration and GST compliance risks. ## What just happened MRC Agrotech Ltd has announced its audited financial results for the fiscal year ended March 31, 2026. On a standalone basis, the company reported a revenue of ₹85.46 crore and a net profit of ₹1.17 crore. Consolidated figures show revenue at ₹89.88 crore and net profit at ₹1.32 crore. ## Why this matters These results indicate the company's operational performance for the fiscal year. The acquisition of Marsapi Lifesciences Private Limited, completed via a share-swap on June 05, 2025, is expected to contribute to the consolidated figures. The loan assignment to Cicago Commodities Private Limited, involving ₹7.30 crore in receivables, signifies a strategic move to settle trade creditor dues. ## The backstory MRC Agrotech operates in the agrochemical and life sciences sector. The acquisition of Marsapi Lifesciences represents a step towards inorganic growth, aiming to expand its market presence and product portfolio. The loan assignment is a financial restructuring move to manage liabilities. ## What changes now The consolidation of Marsapi Lifesciences will impact the group's financial performance going forward. Investors will be looking to see how the integration of the new subsidiary affects future revenues and profitability. The share-swap transaction involved the issuance of 86,42,097 equity shares at ₹19.50 per share. ## Risks to watch Auditors raised concerns regarding GST compliance, specifically the misclassification of exempt supplies under taxable supplies in GSTR-3B filings. A significant business concentration risk was also highlighted, with about 44.62% of taxable outward supplies recognized in March 2026. Furthermore, two related counterparties accounted for a substantial portion of purchases (53%) and sales (23%) during the year. ## Peer comparison Information on specific peers and their financial performance is not detailed in this filing, making a direct comparison difficult based solely on this announcement. ## Context metrics (time-bound) * **Q4 FY26 Standalone Revenue:** ₹65.81 crore * **Q4 FY26 Standalone Net Profit:** ₹0.90 crore * **FY26 Consolidated Revenue:** ₹89.88 crore * **FY26 Consolidated Net Profit:** ₹1.32 crore ## What to track next Investors should closely monitor MRC Agrotech's efforts to rectify GST reporting classifications and how the company manages its business concentration risks. Tracking the performance of the newly acquired Marsapi Lifesciences and the impact of the receivable assignment on its financial health will be crucial.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
